U.S. approves new booster of COVID-19 vaccines, “mix and match” dose

The U.S. Food and Drug Administration (FDA) on Wednesday authorized COVID-19 booster doses of Moderna and Johnson & Johnson, and approved “mix and match” booster dose for currently available approved COVID-19 vaccines.

The agency authorized the use of a single booster dose of the Moderna COVID-19 vaccine at least 6 months after completion of the primary shots to people 65 years of age and older, 18 through 64 years of age at high risk of severe COVID-19, and 18 through 64 years of age with frequent institutional or occupational exposure to SARS-CoV-2.

As for the Johnson & Johnson booster dose, the FDA authorized the use of a single booster dose at least 2 months after completion of the single-dose primary regimen to individuals 18 years of age and older.

A single booster dose of any of the available COVID-19 vaccines may be administered as a “mix and match” booster dose following completion of primary vaccination with a different available COVID-19 vaccine, according to the FDA.

For instance, a person who got a Johnson & Johnson vaccine could receive one from Moderna or Pfizer-BioNTech as a booster.

“The available data suggest waning immunity in some populations who are fully vaccinated,” said Acting FDA Commissioner Janet Woodcock in a statement. “The availability of these authorized boosters is important for continued protection against COVID-19 disease.”

The decision came after an FDA advisory committee voted last week to recommend authorizing Moderna and Johnson & Johnson’s COVID-19 booster doses.

In September, the FDA authorized the first booster shots for the Pfizer-BioNTech COVID-19 vaccine, allowing a single booster dose of the Pfizer-BioNTech vaccine be administered at least 6 months after completion of the primary series to individuals 65 years of age and older, and 18 through 64 years of age with frequent institutional or occupational exposure to SARS-CoV-2.

A recent study of the “mix and match” approach funded by the U.S. National Institutes of Health found no safety concerns using different vaccines as a booster.

The study found that people who received the Johnson & Johnson vaccine produced stronger antibody levels after they got booster shots made by Moderna or Pfizer-BioNTech, compared to boosters from Johnson & Johnson. -rir

Popular

Palace open to SALN transparency, says executive ready to comply

By Darryl John Esguerra | Philippine News Agency Malacañang on Monday expressed support for lifting restrictions on public access to Statements of Assets, Liabilities and...

Palace orders implementation of 10-year plan to boost PH creative industries

By Dean Aubrey Caratiquet As part of the government’s progressive efforts towards growing the country’s creative industries, Malacañang ordered the widespread adoption of the Philippine...

Palace slams Paolo Duterte remarks on ICC’s denial of FPRRD’s request for interim release

By Dean Aubrey Caratiquet The Palace has reiterated that the Marcos Jr. administration has no involvement in the International Criminal Court (ICC) case of former...

PBBM personally visits DavOr to assess quake damages, lead relief efforts

By Dean Aubrey Caratiquet On the heels of an earlier directive to ensure ‘round the clock’ efforts in the wake of the “doublet earthquake” that...